CRIS: Curis Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
1 institutions reported holding $8 of Curis Inc on Form 13F (0 the quarter before). 1 opened a new position and 0 sold out. Shares held by institutions: new.
| Largest holders | Shares | Value |
|---|---|---|
| SBI Securities Co., Ltd. | 15 | $8 |
Clinical trial readouts
2 Phase 2 or 3 trials by Curis Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-07 (est.) | Emavusertib | Relapsed Hematologic Malignancy | Phase 1/2 | 152 | Recruiting | NCT03328078 |
| 2027-11 (est.) | Emavusertib | Chronic Lymphocytic Leukemia | Phase 2 | 108 | Recruiting | NCT07271667 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.